Syndeio Biosciences

Syndeio Biosciences, based in the US, specializes in developing innovative therapies targeting synaptic dysfunction in neuropsychiatric and cognitive disorders, focusing on drug candidates like Zelquistinel and Apimostinel. Founded in 2025 and headquartered in Indianapolis, US, Syndeio Biosciences develops therapies for neuropsychiatric disorders. In May 2025, Syndeio Biosciences raised venture funding led by new investors Innoviva and Catalio Capital Management. New investor Tenmile, Luson Bioventures, Palo Santo, Eli Lilly, AbbVie and Innoviva.

Syndeio Biosciences develops innovative therapies aimed at synaptic dysfunction related to conditions like depression, Alzheimer's, and schizophrenia. Key offerings include Zelquistinel, an oral NMDA receptor modulator for major depressive disorder, and Apimostinel, a rapid-acting injectable for severe central nervous system disorders. Their products are primarily targeted at clinical populations in the United States, with ongoing Phase 2 studies across nearly 30 locations. The company utilizes the Boost Platform™, a proprietary pharmacology model, in collaboration with leading scientific institutions.

Syndeio Biosciences generates revenue through partnerships and collaborations focused on developing and commercializing their therapeutic products. Their business model involves working with healthcare providers and research institutions to conduct clinical trials for their drug candidates. Revenue is anticipated through licensing agreements or partnerships with pharmaceutical companies, especially for their flagship products, Zelquistinel and Apimostinel, as well as potential collaborations utilizing their proprietary Boost Platform™ for drug discovery. Following the recent funding round in May 2025, Syndeio Biosciences plans to advance its drug development initiatives and explore expansion into new markets.

The funds will support the continued development of Zelquistinel and Apimostinel, as well as potential new products targeting other neuropsychiatric conditions. Expansion plans may include increasing clinical trial sites and partnerships in international markets to broaden the reach of their therapies.